Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2502423122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Nikita Sushentsev und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Metabolomics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prostate Cancer UK (ProstateUK), NIHR | NIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC).
Abstract (Originalsprache)
Cribriform prostate cancer (crPCa) is associated with poor clinical outcomes, yet its accurate detection remains challenging due to the poor sensitivity of standard-of-care diagnostic tools. Here, we use untargeted spatial metabolomics to identify fatty acid biosynthesis as a key metabolic pathway enriched in crPCa epithelium. We also show that imaging tumor lipid metabolism using [1- 11 C]acetate PET/CT and proton magnetic resonance spectroscopy differentiates cribriform from noncribriform intermediate-risk prostate cancers in two prospective patient cohorts. These findings support the feasibility of using clinical metabolic imaging techniques as adjunctive tools for improving crPCa detection in clinical practice, with prospective studies in larger cohorts warranted to obtain definitive results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.
- Integrated BioAnalysis, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
- Lewis Group, School of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, United Kingdom.
- Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, United Kingdom.
- Prostate Cancer Centre of Excellence, Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT9 7AE, United Kingdom.
ORCID-Profile: Nikita Sushentsev, Roido Manavaki, Dmitry Soloviev, Luigi Aloj, Ian G Mills, Richard J A Goodwin, Tristan Barrett
Förderung
- Prostate Cancer UK (ProstateUK)
- NIHR | NIHR Cambridge Biomedical Research Centre (NIHR Cambridge BRC)
Zitieren
APA
Sushentsev, N., Hamm, G., Manavaki, R., McLean, M. A., Birchall, J., Soloviev, D., Lewis, D. Y., Aloj, L., Flint, L., Zakirov, A., Mills, I. G., Gnanapragasam, V. J., Warren, A. Y., Barry, S. T., Goodwin, R. J. A., Gallagher, F. A., & Barrett, T. (2025). Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2502423122
Vancouver
Sushentsev N, Hamm G, Manavaki R, McLean MA, Birchall J, Soloviev D, et al. Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2502423122
BibTeX
@article{Sushentsev2025,
author = {Sushentsev, Nikita and Hamm, Gregory and Manavaki, Roido and McLean, Mary A and Birchall, Jonathan and Soloviev, Dmitry and Lewis, David Y and Aloj, Luigi and Flint, Lucy and Zakirov, Aleksandr and Mills, Ian G and Gnanapragasam, Vincent J and Warren, Anne Y and Barry, Simon T and Goodwin, Richard J A and Gallagher, Ferdia A and Barrett, Tristan},
title = {Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2502423122}
}
EUVIMED